Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
Purple Biotech表示,随机2期CM24胰腺癌研究在ASCO 2024年年会上被选为最新摘要海报演讲
Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
Purple Biotech表示,随机2期CM24胰腺癌研究在ASCO 2024年年会上被选为最新摘要海报演讲
使用浏览器的分享功能,分享给你的好友吧